Please login to the form below

Not currently logged in
Email:
Password:

Avodart may help prevent prostate cancer

Findings presented at the American Urological Association's annual meeting show that men at risk of prostate cancer were less likely to develop the disease if treated with GSK's Avodart

Findings presented at the American Urological Association's annual meeting, being held in Chicago, show that men at risk of prostate cancer were less likely to develop the disease if treated with GSK's Avodart (dutasteride).

The Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial studied 8,121 men, aged between 50 and 75 years, with prostate specific antigen (PSA) levels between 2.5 and 10ng/ml (for those aged 50–60 years) and between 3.0 and 10.0 ng/ml (for those over 60 years).

Those taking a daily dose of 0.5 mg of Avodart reduced their risk of biopsy-detectable prostate cancer, over four years, by 23 per cent compared with those taking placebo. A total of 1,516 cancers were observed – 659 among those taking Avodart and 857 in the placebo group.

Avodart inhibits 5-alpha reductase enzymes – type 1 and type 2 –which convert testosterone to dihydrotestosterone (DHT) – a hormone with a key role in prostate growth.

GSK has said that a paper including further analysis of the results of the trial will be submitted for publication this year.

28th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics